TECH
Bio-TechneNASDAQHealth CareBiotechnologySnapshot 2026-05-08
As of May 8, 2026, TECH has a composite score of 1.2 and a signal label of "mixed." The valuation label was changed from "fair" to "full," indicating a shift in perceived value. The scores reflect medium confidence at 72.5, with elevated risk and notable weaknesses in momentum (-23.3) and sector performance (7.6). The top drivers influencing the score include macroeconomic factors such as labor, rates, growth, and inflation.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.08
- Bonus0.00
Why this rank
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $0.57 → $0.52 (-8.3% / 30d). 0 raised, 2 cut, 7 covering analysts.
0 upgrades, 0 downgrades / 30d, 3 maintained. 71% of analysts rate Buy.
3 PT revisions / 30d. Avg target 3.4% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
6 material events in the last 24 months — top 5 listed below.
Stated priorities
2 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Maintain dividend of $0.08 per sharecapital allocationwatchprovisional
5/7: “Bio-Techne announced a cash dividend of $0.08 per share for the quarter ended March 31, 2025.”
Why this status
Stated in 3 of last 3 quarters. Dividend per share has consistently been $0.08 from 2025-Q2 to 2026-Q2. This reflects a stable capital allocation strategy, with no changes in the dividend amount, indicating a consistent payout policy.
- 2.Achieve revenue growthgrowthmixed65% progressprovisional
2/4: “Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.”
Why this status
Stated in 2 of last 2 quarters. Revenue grew from $269.1M in 2025-Q4 to $295.9M in 2026-Q2, indicating progress in growth initiatives. However, the latest quarter's revenue was flat compared to the prior year, suggesting limited progress in achieving further growth.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 78%; 252d 47%.
Drawdown — Max 1y −33%. Bad day move −4%.
Beta to sector ETF (XLV) — 1.54 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 22/100, drawdown 33/100, beta 46/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- label change · valuation_labelseverity 20
Valuation label changed from 'fair' to 'full'.
As of 2026-05-08, the valuation label for TECH changed from 'fair' to 'full'. The forward view indicates an unfavorable scenario with a composite delta estimate of -8.0 if next-quarter guidance is cut, and another unfavorable scenario with a -6.8 estimate if the labor state reverses from -0.31 to +0.31. There are also favorable scenarios, including a +5.0 estimate if the health care sector trend rises to 'improving' and a +4.0 estimate if next-quarter guidance is raised. The overall signal is classified as mixed.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 1 guided quarters · 26.2% avg surprise
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Maintain dividend of $0.08 per share
Capital allocationContinue the dividend policy with a consistent payout of $0.08 per share.
WatchStated in 3 of last 3 quarters. Dividend per share has consistently been $0.08 from 2025-Q2 to 2026-Q2. This reflects a stable capital allocation strategy, with no changes in the dividend amount, indicating a consistent payout policy.
Dividend per share consistently $0.08No scoreCEO/CFO:“Bio-Techne announced a cash dividend of $0.08 per share for the quarter ended March 31, 2025.”Press releaseSource dated 2025-05-07Stated 3 of last 8 quartersFirst seen 2025-05-07provisionalShow history (3)
- 2026-Q2Press release
“Bio-Techne announced a cash dividend of $0.08 per share.”
- 2026-Q1Press release
“Bio-Techne announced a cash dividend of $0.08 per share.”
- 2025-Q2Press release
“Bio-Techne announced a cash dividend of $0.08 per share.”
- #2
Achieve revenue growth
GrowthFocus on increasing revenue through organic and inorganic growth strategies.
MixedStated in 2 of last 2 quarters. Revenue grew from $269.1M in 2025-Q4 to $295.9M in 2026-Q2, indicating progress in growth initiatives. However, the latest quarter's revenue was flat compared to the prior year, suggesting limited progress in achieving further growth.
Revenue grew from $269.1M in 2025-Q4 to $295.9M in 2026-Q265%CEO/CFO:“Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.”8-KSource dated 2026-02-04Stated 2 of last 8 quartersFirst seen 2026-02-04provisionalShow history (2)
- 2026-Q28-K
“Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.”
- 2025-Q48-K
“Revenue was $269.1 million, reflecting growth initiatives.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
TECH Bio-Techne | +1.2 | full | elevated |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-02-04)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-02-04)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-062d agoItem 2.02
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on May 6, 2026, describing the results of operations for the quarter and nine months ended March 31, 2026, and its financial condition as of March 31, 2026 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
earnings preannouncementnegativescore 75 - 2026-05-062d agoItem 8.01
Other Events A copy of the press release issued by Bio-Techne Corporation on May 6, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.
capital allocationneutralscore 49 - 2026-02-112mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Officer Transition On February 11, 2026, Bio-Techne Corporation (the “Company”) announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. In addition, the Compan…
executive changeneutralscore 8 - 2026-02-043mo agoItem 2.02
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on February 4, 2026, describing the results of operations for the quarter and six months ended December 31, 2025, and its financial condition as of December 31, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
earnings preannouncementneutralscore 8 - 2026-02-043mo agoItem 8.01
Other Events A copy of the press release issued by Bio-Techne Corporation on February 4, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.
capital allocationneutralscore 6
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.